Search
Droperidol
go.drugbank.com/drugs/DB00450ApprovedInvestigationalVet approvedIt is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) … It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the
Acetohexamide
go.drugbank.com/drugs/DB00414ApprovedWithdrawnA sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Categories: Drugs Used in DiabetesSynonyms: N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamidePiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigational[A235169] As such, it has become a desirable target for PET imaging of prostate cancer tissues. … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Ozanimod
go.drugbank.com/drugs/DB12612ApprovedInvestigational[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. … It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.
Aflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigational[L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023. … [A261130,L47915] Ziv-aflibercept, under the brand name Zaltrap, was developed as an intravenous injection for the treatment of metastatic colorectal cancer, and it was approved by the FDA and EMA in
Products: EYLEA SOLUTION FOR INJECTION IN VIAL 2MG, EYLEA 40MG/ML SOLUTION FOR INJECTION IN VIALResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigational[L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD
Formaldehyde
go.drugbank.com/drugs/DB03843ApprovedVet approvedIn solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. … (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717)
Categories: Compounds used in a research, industrial, or household settingMepenzolate
go.drugbank.com/drugs/DB04843ApprovedWithdrawnIt has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.
Enasidenib
go.drugbank.com/drugs/DB13874ApprovedInvestigationalThis small molecule acts as an allosteric inhibitor of mutant IDH2 enzyme to prevent cell growth, and it also has shown to block several other enzymes that play a role in abnormal cell differentiation. … First developed by Agios Pharmaceuticals and licensed to Celgene, enasidenib was approved by U.S. Food and Drug Administration on August 1, 2017.
Chloroquine
go.drugbank.com/drugs/DB00608ApprovedInvestigationalVet approved[L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054] … [A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.